Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)MedDRA version: 21.0 Level: PT Classification code 10060121 Term: Squamous cell carcinoma of head and neck System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2016-000725-39-PL
- Lead Sponsor
- Bristol-Myers Squibb International Corporation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- Not specified
- Target Recruitment
- 1329
Histologically confirmed metastatic or recurrent squamous cell
carcinoma of the head and neck (oral cavity, oropharynx, hypopharynx &
XML File Identifier: sPvsDFKWWdER1jFETw4Tet2oTts=
Page 52/67
larynx) that is not amenable to curative therapy.
No prior systemic cancer therapy for recurrent or metastatic disease
(except if chemotherapy was part of multimodal treatment completed 6
months prior to enrolment).
Measurable disease detected by imaging exam (CT or MRI).
Have tumor tissue for PD L1 expression testing, and for oropharyngeal
cancer have results from testing of HPV p16 status
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 930
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 399
Metastatic or recurrent carcinoma of the nasopharynx, squamous cell
carcinoma of unknown primary, squamous cell carcinoma originating
from skin and salivary glands or non squamous histologies (eg. mucosal
melanoma).
No prior treatment with anti PD1, anti PD L1, anti CTLA 4 antibody or any
other antibody or drugs targeting T cell costimulation or checkpoint
pathways, or cetuximab or EGFR inhibitors in any treatment setting.
Patients with certain diseases such as active autoimmune disease, type I
diabetes, hypothyroidism that needs hormone replacement, active
infection, psychiatric disorder.
Inadequate hematologic, renal or hepatic function.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method